Cargando…

Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer

The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association be...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lei, Song, Peng, Xue, Xuemin, Guo, Changyuan, Han, Liankui, Fang, Qing, Ying, Jianming, Gao, Shugeng, Li, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587215/
https://www.ncbi.nlm.nih.gov/pubmed/31145232
http://dx.doi.org/10.1097/CJI.0000000000000275
_version_ 1783429021764157440
author Guo, Lei
Song, Peng
Xue, Xuemin
Guo, Changyuan
Han, Liankui
Fang, Qing
Ying, Jianming
Gao, Shugeng
Li, Wenbin
author_facet Guo, Lei
Song, Peng
Xue, Xuemin
Guo, Changyuan
Han, Liankui
Fang, Qing
Ying, Jianming
Gao, Shugeng
Li, Wenbin
author_sort Guo, Lei
collection PubMed
description The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association between chemotherapy response, prognosis and the variation of PD-L1 expression in lung cancer patients. A total of 63 lung cancer patients who received platinum-based neoadjuvant chemotherapy and subsequently underwent surgical resection were selected. PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) was assessed by immunohistochemistry using 22C3 monoclonal antibody in these 63 matched lung cancer specimens before and after neoadjuvant chemotherapy. The positivity of PD-L1 on TC changed from 17.5% to 39.7% after neoadjuvant chemotherapy and the positivity of PD-L1 on IC changed from 19.0% to 71.4% after neoadjuvant chemotherapy. The elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was more frequently observed in patients achieving stable disease or progressive disease than in patients achieving partial response (P=0.026). Patients with elevated PD-L1 expression on TC after neoadjuvant chemotherapy showed a trend to have a shorter progression-free survival than patients without elevated PD-L1 expression on TC, although the difference was not statistically significant in multivariate analysis (hazard ratio=2.38, 95% confidence interval=0.99–5.73, P=0.053). PD-L1 expression can be elevated by chemotherapy in lung cancer. Furthermore, elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was associated with reduced chemotherapy response and inferior progression-free survival in patients with lung cancer.
format Online
Article
Text
id pubmed-6587215
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-65872152019-07-22 Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer Guo, Lei Song, Peng Xue, Xuemin Guo, Changyuan Han, Liankui Fang, Qing Ying, Jianming Gao, Shugeng Li, Wenbin J Immunother Clinical Studies The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association between chemotherapy response, prognosis and the variation of PD-L1 expression in lung cancer patients. A total of 63 lung cancer patients who received platinum-based neoadjuvant chemotherapy and subsequently underwent surgical resection were selected. PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) was assessed by immunohistochemistry using 22C3 monoclonal antibody in these 63 matched lung cancer specimens before and after neoadjuvant chemotherapy. The positivity of PD-L1 on TC changed from 17.5% to 39.7% after neoadjuvant chemotherapy and the positivity of PD-L1 on IC changed from 19.0% to 71.4% after neoadjuvant chemotherapy. The elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was more frequently observed in patients achieving stable disease or progressive disease than in patients achieving partial response (P=0.026). Patients with elevated PD-L1 expression on TC after neoadjuvant chemotherapy showed a trend to have a shorter progression-free survival than patients without elevated PD-L1 expression on TC, although the difference was not statistically significant in multivariate analysis (hazard ratio=2.38, 95% confidence interval=0.99–5.73, P=0.053). PD-L1 expression can be elevated by chemotherapy in lung cancer. Furthermore, elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was associated with reduced chemotherapy response and inferior progression-free survival in patients with lung cancer. Lippincott Williams & Wilkins 2019 2019-05-28 /pmc/articles/PMC6587215/ /pubmed/31145232 http://dx.doi.org/10.1097/CJI.0000000000000275 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Clinical Studies
Guo, Lei
Song, Peng
Xue, Xuemin
Guo, Changyuan
Han, Liankui
Fang, Qing
Ying, Jianming
Gao, Shugeng
Li, Wenbin
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title_full Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title_fullStr Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title_full_unstemmed Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title_short Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
title_sort variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587215/
https://www.ncbi.nlm.nih.gov/pubmed/31145232
http://dx.doi.org/10.1097/CJI.0000000000000275
work_keys_str_mv AT guolei variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT songpeng variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT xuexuemin variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT guochangyuan variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT hanliankui variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT fangqing variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT yingjianming variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT gaoshugeng variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer
AT liwenbin variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer